Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82374554)
- National Natural Science Foundation of China (CRD42024565784)
This publication has 73 references indexed in Scilit:
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination TreatmentJAMA Network Open, 2024
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 DiabetesJAMA, 2023
- Glucagon‐like peptide‐1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta‐analysis of randomized controlled trialsDiabetes/Metabolism Research and Reviews, 2019
- Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?Diabetes/Metabolism Research and Reviews, 2018
- Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetologia, 2015
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 DiabetesJAMA, 2015
- Diabetes mellitus and risk of hip fractures: a meta-analysisOsteoporosis International, 2015
- Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trialsEndocrine, 2014
- Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trialDiabetologia, 2013
- A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia, 2006